Neurocrine Bio. (NBIX) PT Raised to $119 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $168.58 +15.98%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 13
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 13
Join SI Premium – FREE
Mizuho Securities analyst Vamil Divan raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $119.00 (from $117.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
- Hinge Health Inc (HNGE) PT Raised to $135 at Stifel
- Avita Medical Ltd. (RCEL) PT Raised to $20 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
